1
|
Jackson JJ, Siegmund AC, Bai WJ, Reed AB, Birkholz AB, Campuzano IDG, Créquer-Grandhomme A, Hu R, Modak RV, Sudom A, Javier N, Sanders C, Lo MC, Xie F, Cee VJ, Manzanillo P, Allen JG. Imidazolone as an Amide Bioisostere in the Development of β-1,3- N-Acetylglucosaminyltransferase 2 (B3GNT2) Inhibitors. J Med Chem 2023; 66:16120-16140. [PMID: 37988652 DOI: 10.1021/acs.jmedchem.3c01517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2023]
Abstract
B3GNT2 is responsible for elongation of cell surface long-chain polylactosamine, which influences the regulation of the immune response, making it an attractive target for immunomodulation. In the development of amide containing B3GNT2 inhibitors guided by structure-based drug design, imidazolones were found to successfully serve as amide bioisosteres. This novel imidazolone isosteric strategy alleviated torsional strain of the amide bond on binding to B3GNT2 and improved potency, isoform selectivity, as well as certain physicochemical and pharmacokinetic properties. Herein, we present the synthesis, SAR, X-ray cocrystal structures, and in vivo PK properties of imidazol-4-ones in the context of B3GNT2 inhibition.
Collapse
Affiliation(s)
- Jeffrey J Jackson
- Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Aaron C Siegmund
- Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Wen-Ju Bai
- Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Anthony B Reed
- Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Adam B Birkholz
- Center for Research Acceleration by Digital Innovation, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Iain D G Campuzano
- Center for Research Acceleration by Digital Innovation, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Amandine Créquer-Grandhomme
- Inflammation, Amgen Research, Amgen Inc., 750 Gateway Blvd, Ste 100, South San Francisco, California 94080, United States
| | - Ruozhen Hu
- Inflammation, Amgen Research, Amgen Inc., 750 Gateway Blvd, Ste 100, South San Francisco, California 94080, United States
| | - Rucha V Modak
- Inflammation, Amgen Research, Amgen Inc., 750 Gateway Blvd, Ste 100, South San Francisco, California 94080, United States
| | - Athena Sudom
- Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Noelle Javier
- Lead Discovery & Characterization, Amgen Research, Amgen Inc., 750 Gateway Blvd, Ste 100, South San Francisco, California 94080, United States
| | - Christiana Sanders
- Lead Discovery & Characterization, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Mei-Chu Lo
- Lead Discovery & Characterization, Amgen Research, Amgen Inc., 750 Gateway Blvd, Ste 100, South San Francisco, California 94080, United States
| | - Fang Xie
- Pharmacokinetics & Drug Metabolism, Amgen Research, Amgen Inc., 750 Gateway Blvd, Ste 100, South San Francisco, California 94080, United States
| | - Victor J Cee
- Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| | - Paolo Manzanillo
- Inflammation, Amgen Research, Amgen Inc., 750 Gateway Blvd, Ste 100, South San Francisco, California 94080, United States
| | - John G Allen
- Small Molecule Therapeutic Discovery, Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
2
|
Jackson JJ, Shibuya GM, Ravishankar B, Adusumilli L, Bradford D, Brockstedt DG, Bucher C, Bui M, Cho C, Colas C, Cutler G, Dukes A, Han X, Hu DX, Jacobson S, Kassner PD, Katibah GE, Ko MYM, Kolhatkar U, Leger PR, Ma A, Marshall L, Maung J, Ng AA, Okano A, Pookot D, Poon D, Ramana C, Reilly MK, Robles O, Schwarz JB, Shakhmin AA, Shunatona HP, Sreenivasan R, Tivitmahaisoon P, Xu M, Zaw T, Wustrow DJ, Zibinsky M. Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy. J Med Chem 2022; 65:12895-12924. [PMID: 36127295 DOI: 10.1021/acs.jmedchem.2c00736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
General control nonderepressible 2 (GCN2) protein kinase is a cellular stress sensor within the tumor microenvironment (TME), whose signaling cascade has been proposed to contribute to immune escape in tumors. Herein, we report the discovery of cell-potent GCN2 inhibitors with excellent selectivity against its closely related Integrated Stress Response (ISR) family members heme-regulated inhibitor kinase (HRI), protein kinase R (PKR), and (PKR)-like endoplasmic reticulum kinase (PERK), as well as good kinome-wide selectivity and favorable PK. In mice, compound 39 engages GCN2 at levels ≥80% with an oral dose of 15 mg/kg BID. We also demonstrate the ability of compound 39 to alleviate MDSC-related T cell suppression and restore T cell proliferation, similar to the effect seen in MDSCs from GCN2 knockout mice. In the LL2 syngeneic mouse model, compound 39 demonstrates significant tumor growth inhibition (TGI) as a single agent. Furthermore, TGI mediated by anti-VEGFR was enhanced by treatment with compound 39 demonstrating the complementarity of these two mechanisms.
Collapse
Affiliation(s)
- Jeffrey J Jackson
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Grant M Shibuya
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Buvana Ravishankar
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Lavanya Adusumilli
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Delia Bradford
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Dirk G Brockstedt
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Cyril Bucher
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Minna Bui
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Cynthia Cho
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Christoph Colas
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Gene Cutler
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Adrian Dukes
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Xinping Han
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Dennis X Hu
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Scott Jacobson
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Paul D Kassner
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - George E Katibah
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Michelle Yoo Min Ko
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Urvi Kolhatkar
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Paul R Leger
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Anqi Ma
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Lisa Marshall
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Jack Maung
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Andrew A Ng
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Akinori Okano
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Deepa Pookot
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Daniel Poon
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Chandru Ramana
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Maureen K Reilly
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Omar Robles
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Jacob B Schwarz
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Anton A Shakhmin
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Hunter P Shunatona
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Raashi Sreenivasan
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | | | - Mengshu Xu
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Thant Zaw
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - David J Wustrow
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| | - Mikhail Zibinsky
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California94080, United States
| |
Collapse
|
3
|
Jorapur A, Marshall LA, Jacobson S, Xu M, Marubayashi S, Zibinsky M, Hu DX, Robles O, Jackson JJ, Baloche V, Busson P, Wustrow D, Brockstedt DG, Talay O, Kassner PD, Cutler G. EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22. PLoS Pathog 2022; 18:e1010200. [PMID: 35025968 PMCID: PMC8791514 DOI: 10.1371/journal.ppat.1010200] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 01/26/2022] [Accepted: 12/13/2021] [Indexed: 12/15/2022] Open
Abstract
The Epstein-Barr Virus (EBV) is involved in the etiology of multiple hematologic and epithelial human cancers. EBV+ tumors employ multiple immune escape mechanisms, including the recruitment of immunosuppressive regulatory T cells (Treg). Here, we show some EBV+ tumor cells express high levels of the chemokines CCL17 and CCL22 both in vitro and in vivo and that this expression mirrors the expression levels of expression of the EBV LMP1 gene in vitro. Patient samples from lymphoblastic (Hodgkin lymphoma) and epithelial (nasopharyngeal carcinoma; NPC) EBV+ tumors revealed CCL17 and CCL22 expression of both tumor cell-intrinsic and -extrinsic origin, depending on tumor type. NPCs grown as mouse xenografts likewise showed both mechanisms of chemokine production. Single cell RNA-sequencing revealed in vivo tumor cell-intrinsic CCL17 and CCL22 expression combined with expression from infiltrating classical resident and migratory dendritic cells in a CT26 colon cancer mouse tumor engineered to express LMP1. These data suggest that EBV-driven tumors employ dual mechanisms for CCL17 and CCL22 production. Importantly, both in vitro and in vivo Treg migration was effectively blocked by a novel, small molecule antagonist of CCR4, CCR4-351. Antagonism of the CCR4 receptor may thus be an effective means of activating the immune response against a wide spectrum of EBV+ tumors.
Collapse
Affiliation(s)
- Aparna Jorapur
- Discovery Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Lisa A. Marshall
- Quantitative Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Scott Jacobson
- Discovery Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Mengshu Xu
- Computational Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Sachie Marubayashi
- Discovery Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Mikhail Zibinsky
- Drug Discovery, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Dennis X. Hu
- Drug Discovery, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Omar Robles
- Drug Discovery, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Jeffrey J. Jackson
- Drug Discovery, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Valentin Baloche
- CNRS-UMR 8126, Gustave Roussy and Paris-Sud/Paris-Saclay University, Villejuif, France
| | - Pierre Busson
- CNRS-UMR 8126, Gustave Roussy and Paris-Sud/Paris-Saclay University, Villejuif, France
| | - David Wustrow
- Drug Discovery, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Dirk G. Brockstedt
- Discovery Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Oezcan Talay
- Discovery Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Paul D. Kassner
- Quantitative Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| | - Gene Cutler
- Computational Biology, RAPT Therapeutics, Inc., South San Francisco, California, United States of America
| |
Collapse
|
4
|
Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, Hu DX, Jackson JJ, Pookot D, Sanchez J, Brovarney M, Wadsworth A, Chian D, Wustrow D, Kassner PD, Cutler G, Wong B, Brockstedt DG, Talay O. Tumors establish resistance to immunotherapy by regulating T reg recruitment via CCR4. J Immunother Cancer 2021; 8:jitc-2020-000764. [PMID: 33243932 PMCID: PMC7692993 DOI: 10.1136/jitc-2020-000764] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/25/2020] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Checkpoint inhibitors (CPIs) such as anti-PD(L)-1 and anti-CTLA-4 antibodies have resulted in unprecedented rates of antitumor responses and extension of survival of patients with a variety of cancers. But some patients fail to respond or initially respond but later relapse as they develop resistance to immune therapy. One of the tumor-extrinsic mechanisms for resistance to immune therapy is the accumulation of regulatory T cells (Treg) in tumors. In preclinical and clinical studies, it has been suggested that tumor trafficking of Treg is mediated by CC chemokine receptor 4 (CCR4). Over 90% of human Treg express CCR4 and migrate toward CCL17 and CCL22, two major CCR4 ligands that are either high at baseline or upregulated in tumors on CPI treatment. Hence, CCR4 antagonism has the potential to be an effective antitumor treatment by reducing the accumulation of Treg into the tumor microenvironment (TME). METHODS We developed in vitro and in vivo models to assess Treg migration and antitumor efficacy using a potent and selective CCR4 antagonist, CCR4-351. We used two separate tumor models, Pan02 and CT26 mouse tumors, that have high and low CCR4 ligand expression, respectively. Tumor growth inhibition as well as the frequency of tumor-infiltrating Treg and effector T cells was assessed following the treatment with CCR4 antagonist alone or in combination with CPI. RESULTS Using a selective and highly potent, novel small molecule inhibitor of CCR4, we demonstrate that migration of CCR4+ Treg into the tumor drives tumor progression and resistance to CPI treatment. In tumor models with high baseline levels of CCR4 ligands, blockade of CCR4 reduced the number of Treg and enhanced antitumor immune activity. Notably, in tumor models with low baseline level of CCR4 ligands, treatment with immune CPIs resulted in significant increases of CCR4 ligands and Treg numbers. Inhibition of CCR4 reduced Treg frequency and potentiated the antitumor effects of CPIs. CONCLUSION Taken together, we demonstrate that CCR4-dependent Treg recruitment into the tumor is an important tumor-extrinsic mechanism for immune resistance. Blockade of CCR4 led to reduced frequency of Treg and resulted in increased antitumor activity, supporting the clinical development of CCR4 inhibitors in combination with CPI for the treatment of cancer. STATEMENT OF SIGNIFICANCE CPI upregulates CCL17 and CCL22 expression in tumors and increases Treg migration into the TME. Pharmacological antagonism of the CCR4 receptor effectively inhibits Treg recruitment and results in enhanced antitumor efficacy either as single agent in CCR4 ligandhigh tumors or in combination with CPIs in CCR4 ligandlow tumors.
Collapse
Affiliation(s)
| | | | | | | | | | - Omar Robles
- RAPT Therapeutics, South San Francisco, California, USA
| | | | | | - Deepa Pookot
- RAPT Therapeutics, South San Francisco, California, USA
| | | | | | | | - David Chian
- Lyell Immunopharma, South San Francisco, California, USA
| | - David Wustrow
- RAPT Therapeutics, South San Francisco, California, USA
| | | | - Gene Cutler
- RAPT Therapeutics, South San Francisco, California, USA
| | - Brian Wong
- RAPT Therapeutics, South San Francisco, California, USA
| | | | - Oezcan Talay
- RAPT Therapeutics, South San Francisco, California, USA
| |
Collapse
|
5
|
Podunavac M, Mailyan AK, Jackson JJ, Lovy A, Farias P, Huerta H, Molgó J, Cardenas C, Zakarian A. Scalable Total Synthesis, IP3R Inhibitory Activity of Desmethylxestospongin B, and Effect on Mitochondrial Function and Cancer Cell Survival. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202102259] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Maša Podunavac
- Department of Chemistry and Biochemistry University of California Santa Barbara Santa Barbara CA 93106 USA
| | - Artur K. Mailyan
- Department of Chemistry and Biochemistry University of California Santa Barbara Santa Barbara CA 93106 USA
| | - Jeffrey J. Jackson
- Department of Chemistry and Biochemistry University of California Santa Barbara Santa Barbara CA 93106 USA
| | - Alenka Lovy
- Center for Integrative Biology Faculty of Sciences Geroscience Center for Brain Health and Metabolism Universidad Mayor Santiago Chile
| | - Paula Farias
- Center for Integrative Biology Faculty of Sciences Geroscience Center for Brain Health and Metabolism Universidad Mayor Santiago Chile
| | - Hernan Huerta
- Center for Integrative Biology Faculty of Sciences Geroscience Center for Brain Health and Metabolism Universidad Mayor Santiago Chile
| | - Jordi Molgó
- Université Paris-Saclay CEA Institut des Sciences du Vivant Frédéric Joliot ERL CNRS n 9004 Département Médicaments et Technologies pour la Santé Service d'Ingéniere Moléculaire pour Santé (SIMoS) Batiment 152, Point courrier 24 91191 Gif-sur-Yvette France
| | - Cesar Cardenas
- Department of Chemistry and Biochemistry University of California Santa Barbara Santa Barbara CA 93106 USA
- Center for Integrative Biology Faculty of Sciences Geroscience Center for Brain Health and Metabolism Universidad Mayor Santiago Chile
- The Buck Institute for Research on Aging Novato CA USA
| | - Armen Zakarian
- Department of Chemistry and Biochemistry University of California Santa Barbara Santa Barbara CA 93106 USA
| |
Collapse
|
6
|
Podunavac M, Mailyan AK, Jackson JJ, Lovy A, Farias P, Huerta H, Molgó J, Cardenas C, Zakarian A. Scalable Total Synthesis, IP3R Inhibitory Activity of Desmethylxestospongin B, and Effect on Mitochondrial Function and Cancer Cell Survival. Angew Chem Int Ed Engl 2021; 60:11278-11282. [PMID: 33751770 DOI: 10.1002/anie.202102259] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Indexed: 11/05/2022]
Abstract
The scalable synthesis of the oxaquinolizidine marine natural product desmethylxestospongin B is based on the early application of Ireland-Claisen rearrangement, macrolactamization, and a late-stage installation of the oxaquinolizidine units by lactam reduction. The synthesis serves as the source of material to investigate calcium signaling and its effect on mitochondrial metabolism in various cell types, including cancer cells.
Collapse
Affiliation(s)
- Maša Podunavac
- Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Artur K Mailyan
- Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Jeffrey J Jackson
- Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Alenka Lovy
- Center for Integrative Biology, Faculty of Sciences, Geroscience Center for Brain Health and Metabolism, Universidad Mayor, Santiago, Chile
| | - Paula Farias
- Center for Integrative Biology, Faculty of Sciences, Geroscience Center for Brain Health and Metabolism, Universidad Mayor, Santiago, Chile
| | - Hernan Huerta
- Center for Integrative Biology, Faculty of Sciences, Geroscience Center for Brain Health and Metabolism, Universidad Mayor, Santiago, Chile
| | - Jordi Molgó
- Université Paris-Saclay, CEA, Institut des Sciences du Vivant Frédéric Joliot, ERL CNRS n 9004, Département Médicaments et Technologies pour la Santé, Service d'Ingéniere Moléculaire pour Santé (SIMoS), Batiment 152, Point courrier 24, 91191, Gif-sur-Yvette, France
| | - Cesar Cardenas
- Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA, 93106, USA.,Center for Integrative Biology, Faculty of Sciences, Geroscience Center for Brain Health and Metabolism, Universidad Mayor, Santiago, Chile.,The Buck Institute for Research on Aging, Novato, CA, USA
| | - Armen Zakarian
- Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, CA, 93106, USA
| |
Collapse
|
7
|
Robles O, Jackson JJ, Marshall L, Talay O, Chian D, Cutler G, Diokno R, Hu DX, Jacobson S, Karbarz E, Kassner PD, Ketcham JM, McKinnell J, Meleza C, Reilly MK, Riegler E, Shunatona HP, Wadsworth A, Younai A, Brockstedt DG, Wustrow DJ, Zibinsky M. Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors. J Med Chem 2020; 63:8584-8607. [PMID: 32667798 DOI: 10.1021/acs.jmedchem.0c00988] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The C-C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (Treg) as well as other circulating and tissue-resident T cells. Treg can be recruited to the tumor microenvironment (TME) through the C-C chemokines CCL17 and CCL22. Treg accumulation in the TME has been shown to dampen the antitumor immune response and is thought to be an important driver in tumor immune evasion. Preclinical and clinical data suggest that reducing the Treg population in the TME can potentiate the antitumor immune response of checkpoint inhibitors. We have developed small-molecule antagonists of CCR4, featuring a novel piperidinyl-azetidine motif, that inhibit the recruitment of Treg into the TME and elicit antitumor responses as a single agent or in combination with an immune checkpoint blockade. The discovery of these potent, selective, and orally bioavailable CCR4 antagonists, and their activity in in vitro and in vivo models, is described herein.
Collapse
Affiliation(s)
- Omar Robles
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Jeffrey J Jackson
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Lisa Marshall
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Oezcan Talay
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - David Chian
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Gene Cutler
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Raymond Diokno
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Dennis X Hu
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Scott Jacobson
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Emily Karbarz
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Paul D Kassner
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - John M Ketcham
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Jenny McKinnell
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Cesar Meleza
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Maureen K Reilly
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Erin Riegler
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Hunter P Shunatona
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Angela Wadsworth
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Ashkaan Younai
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Dirk G Brockstedt
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - David J Wustrow
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Mikhail Zibinsky
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| |
Collapse
|
8
|
Jackson JJ, Ketcham JM, Younai A, Abraham B, Biannic B, Beck HP, Bui MHT, Chian D, Cutler G, Diokno R, Hu DX, Jacobson S, Karbarz E, Kassner PD, Marshall L, McKinnell J, Meleza C, Okal A, Pookot D, Reilly MK, Robles O, Shunatona HP, Talay O, Walker JR, Wadsworth A, Wustrow DJ, Zibinsky M. Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment. J Med Chem 2019; 62:6190-6213. [DOI: 10.1021/acs.jmedchem.9b00506] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Jeffrey J. Jackson
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - John M. Ketcham
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Ashkaan Younai
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Betty Abraham
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Berenger Biannic
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Hilary P. Beck
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Minna H. T. Bui
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - David Chian
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Gene Cutler
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Raymond Diokno
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Dennis X. Hu
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Scott Jacobson
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Emily Karbarz
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Paul D. Kassner
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Lisa Marshall
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Jenny McKinnell
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Cesar Meleza
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Abood Okal
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Deepa Pookot
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Maureen K. Reilly
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Omar Robles
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Hunter P. Shunatona
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Oezcan Talay
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - James R. Walker
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Angela Wadsworth
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - David J. Wustrow
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Mikhail Zibinsky
- RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States
| |
Collapse
|
9
|
Fournier J, Chen K, Mailyan AK, Jackson JJ, Buckman BO, Emayan K, Yuan S, Rajagopalan R, Misialek S, Adler M, Blaesse M, Griessner A, Zakarian A. Total Synthesis of Covalent Cysteine Protease Inhibitor N-Desmethyl Thalassospiramide C and Crystallographic Evidence for Its Mode of Action. Org Lett 2019; 21:508-512. [DOI: 10.1021/acs.orglett.8b03821] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jeremy Fournier
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93111, United States
| | - Karen Chen
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93111, United States
| | - Artur K. Mailyan
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93111, United States
| | - Jeffrey J. Jackson
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93111, United States
| | - Brad O. Buckman
- Blade Therapeutics, 442 Littlefield Avenue, South San Francisco, California 94080, United States
| | - Kumar Emayan
- Bayside Pharma, 2600 Hilltop Drive, Richmond, California 94806, United States
| | - Shendong Yuan
- Bayside Pharma, 2600 Hilltop Drive, Richmond, California 94806, United States
| | - Ravi Rajagopalan
- Blade Therapeutics, 442 Littlefield Avenue, South San Francisco, California 94080, United States
| | - Shawn Misialek
- Blade Therapeutics, 442 Littlefield Avenue, South San Francisco, California 94080, United States
| | - Marc Adler
- ChemPartner, 280 Utah Avenue Suite 100, South San Francisco, California 94080, United States
| | - Michael Blaesse
- Proteros Biostructures GmbH, Bunsenstraße 7 a, 82152 Planegg-Martinsried, Germany
| | - Andreas Griessner
- Proteros Biostructures GmbH, Bunsenstraße 7 a, 82152 Planegg-Martinsried, Germany
| | - Armen Zakarian
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93111, United States
| |
Collapse
|
10
|
Yu K, Lu P, Jackson JJ, Nguyen TAD, Alvarado J, Stivala CE, Ma Y, Mack KA, Hayton TW, Collum DB, Zakarian A. Lithium Enolates in the Enantioselective Construction of Tetrasubstituted Carbon Centers with Chiral Lithium Amides as Noncovalent Stereodirecting Auxiliaries. J Am Chem Soc 2017; 139:527-533. [PMID: 27997174 PMCID: PMC6097510 DOI: 10.1021/jacs.6b11673] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Lithium enolates derived from carboxylic acids are ubiquitous intermediates in organic synthesis. Asymmetric transformations with these intermediates, a central goal of organic synthesis, are typically carried out with covalently attached chiral auxiliaries. An alternative approach is to utilize chiral reagents that form discrete, well-defined aggregates with lithium enolates, providing a chiral environment conducive of asymmetric bond formation. These reagents effectively act as noncovalent, or traceless, chiral auxiliaries. Lithium amides are an obvious choice for such reagents as they are known to form mixed aggregates with lithium enolates. We demonstrate here that mixed aggregates can effect highly enantioselective transformations of lithium enolates in several classes of reactions, most notably in transformations forming tetrasubstituted and quaternary carbon centers. Easy recovery of the chiral reagent by aqueous extraction is another practical advantage of this one-step protocol. Crystallographic, spectroscopic, and computational studies of the central reactive aggregate, which provide insight into the origins of selectivity, are also reported.
Collapse
Affiliation(s)
- Kai Yu
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| | - Ping Lu
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| | - Jeffrey J Jackson
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| | - Thuy-Ai D Nguyen
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| | - Joseph Alvarado
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| | - Craig E Stivala
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| | - Yun Ma
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University , Ithaca, New York 14853, United States
| | - Kyle A Mack
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University , Ithaca, New York 14853, United States
| | - Trevor W Hayton
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| | - David B Collum
- Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University , Ithaca, New York 14853, United States
| | - Armen Zakarian
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| |
Collapse
|
11
|
Jackson JJ, Kobayashi H, Steffens SD, Zakarian A. 10-Step Asymmetric Total Synthesis and Stereochemical Elucidation of (+)-Dragmacidin D. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201504113] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
12
|
Jackson JJ, Kobayashi H, Steffens SD, Zakarian A. 10-Step Asymmetric Total Synthesis and Stereochemical Elucidation of (+)-Dragmacidin D. Angew Chem Int Ed Engl 2015; 54:9971-5. [PMID: 26130270 DOI: 10.1002/anie.201504113] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2015] [Indexed: 12/22/2022]
Abstract
The asymmetric synthesis of dragmacidin D (1) was completed in 10 steps. Its sole stereocenter was set by using direct asymmetric alkylation enabled by a C2-symmetric tetramine and lithium N-(trimethylsilyl)-tert-butylamide as the enolization reagent. A central Larock indole synthesis was employed in a convergent assembly of the heterocyclic subunits. The stereochemical evidence from this work strongly supports the predicted S configuration at the 6''' position, which is consistent with other members of the dragmacidin family of natural products.
Collapse
Affiliation(s)
- Jeffrey J Jackson
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA 93106-9510 (USA)
| | - Hiroyuki Kobayashi
- Daiichi Sankyo Co., LTD, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710 (Japan)
| | - Sophia D Steffens
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA 93106-9510 (USA)
| | - Armen Zakarian
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA 93106-9510 (USA).
| |
Collapse
|
13
|
Lu P, Jackson JJ, Eickhoff JA, Zakarian A. Direct enantioselective conjugate addition of carboxylic acids with chiral lithium amides as traceless auxiliaries. J Am Chem Soc 2015; 137:656-9. [PMID: 25562717 PMCID: PMC4308744 DOI: 10.1021/ja512213c] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Michael addition is a premier synthetic method for carbon-carbon and carbon-heteroatom bond formation. Using chiral dilithium amides as traceless auxiliaries, we report the direct enantioselective Michael addition of carboxylic acids. A free carboxyl group in the product provides versatility for further functionalization, and the chiral reagent can be readily recovered by extraction with aqueous acid. The method has been applied in the enantioselective total synthesis of the purported structure of pulveraven B.
Collapse
Affiliation(s)
- Ping Lu
- Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
| | | | | | | |
Collapse
|
14
|
Xiao Q, Jackson JJ, Basak A, Bowler JM, Miller BG, Zakarian A. Enantioselective synthesis of tatanans A-C and reinvestigation of their glucokinase-activating properties. Nat Chem 2013; 5:410-6. [PMID: 23609092 PMCID: PMC4126512 DOI: 10.1038/nchem.1597] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2012] [Accepted: 02/07/2013] [Indexed: 01/31/2023]
Abstract
The tatanans are members of a novel class of complex sesquilignan natural products recently isolated from the rhizomes of Acorus tatarinowii Schott plants. Tatanans A, B and C have previously been reported to have potent glucokinase-activating properties that exceed the in vitro activity of known synthetic antidiabetic agents. Here, using a series of sequential [3,3]-sigmatropic rearrangements, we report the total synthesis of tatanan A in 13 steps and 13% overall yield. We also complete a concise enantioselective total synthesis of more complex, atropisomeric tatanans B and C via a distinct convergent strategy based on a palladium-catalysed diastereotopic aromatic group differentiation (12 steps, 4% and 8% overall yield, respectively). A plausible biosynthetic relationship between acyclic tatanan A and spirocyclic tatanans B and C is proposed and probed experimentally. With sufficient quantities of the natural products in hand, we undertake a detailed functional characterization of the biological activities of tatanans A-C. Contrary to previous reports, our assays utilizing pure recombinant human enzyme demonstrate that tatanans do not function as allosteric activators of glucokinase.
Collapse
Affiliation(s)
- Qing Xiao
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106, USA
| | - Jeffrey J. Jackson
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106, USA
| | - Ashok Basak
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106, USA
| | - Joseph M. Bowler
- Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida 32306-4390, USA
| | - Brian G. Miller
- Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida 32306-4390, USA
| | - Armen Zakarian
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106, USA
| |
Collapse
|
15
|
Jackson JJ, Stivala CE, Iorga BI, Molgó J, Zakarian A. Stability of cyclic imine toxins: interconversion of pinnatoxin amino ketone and pinnatoxin A in aqueous media. J Org Chem 2012; 77:10435-40. [PMID: 23116445 DOI: 10.1021/jo301632d] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Pinnatoxins belong to the cyclic imine (CI) group of marine toxins with a unique toxicological profile. The need for structural integrity of the aliphatic 7-membered cyclic imine for the potent bioactivity of pinnatoxins has been experimentally demonstrated. In this study, we probe interconversion of the natural cyclic imine and its open form, pinnatoxin A amino ketone (PnTX AK), under physiologically relevant aqueous conditions. Our studies demonstrate the high stability of PnTX A. The unusual stability of the imine ring in PnTX A has implications for its oral toxicity and detoxification. These studies, as well the access to PnTX amino ketone, were enabled by the total synthesis of (+)-pinnatoxin A completed previously in our laboratory.
Collapse
Affiliation(s)
- Jeffrey J Jackson
- Department of Chemistry and Biochemistry, University of California, Santa Barbara, California 93106-9510, USA
| | | | | | | | | |
Collapse
|
16
|
Shapiro DI, Obrycki JJ, Lewis LC, Jackson JJ. Effects of Crop Residue on the Persistence of Steinernema carpocapsae. J Nematol 1999; 31:517-519. [PMID: 19270924 PMCID: PMC2620390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
We determined the effects of crop residue on the persistence of an entomopathogenic nematode, Steinernema carpocapsae. During 2 consecutive years, nematodes were applied at rates of 2.5 x 10 and 1.0 x 10 infective juveniles/m(2) to small field plots planted with corn. Nematode persistence was monitored by exposing Galleria mellonella larvae to soil samples from plots with and without crop residue (approximately 75% coverage of soybean stubble). Persistence of S. carpocapsae was significantly greater in crop residue plots than in plots without residue. In crop residue plots that received the higher rate of nematode application, larval mortality did not significantly decrease during the study period (3 to 5 days) and remained above 85%. In nematode-treated plots without crop residue, however, larval mortality fell from over 96% to below 11% and 35% in the first and second trials, respectively. The increased crop residue may have benefited nematode persistence through protection from desiccation or ultraviolet light. We conclude that increased ground cover in cropping systems (e.g., due to reduced tillage) may lead to increased insect pest suppression with entomopathogenic nematodes.
Collapse
|
17
|
Ernst EJ, Hashimoto S, Guglielmo J, Sawa T, Pittet JF, Kropp H, Jackson JJ, Wiener-Kronish JP. Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model. Antimicrob Agents Chemother 1999; 43:2389-94. [PMID: 10508012 PMCID: PMC89488 DOI: 10.1128/aac.43.10.2389] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The effect of antibiotics on the acute lung injury induced by virulent Pseudomonas aeruginosa PA103 was quantitatively analyzed in a rat model. Lung injury was induced by the instillation of PA103 directly into the right lower lobes of the lungs of anesthetized rats. The alveolar epithelial injury, extravascular lung water, and total plasma equivalents were measured as separate, independent parameters of acute lung injury. Four hours after the instillation of PA103, all the parameters were increased linearly depending on the dose of P. aeruginosa. Next, we examined the effects of intravenously administered antibiotics on the parameters of acute lung injury in D-galactosamine-sensitized rats. One hour after the rats received 10(7) CFU of PA103, an intravenous bolus injection of aztreonam (60 mg/kg) or imipenem-cilastatin (30 mg/kg) was administered. Despite an MIC indicating resistance, imipenem-cilastatin improved all the measurements of lung injury; in contrast, aztreonam, which had an MIC indicating sensitivity, did not improve any of the lung injury parameters. The antibiotics did not generate different quantities of plasma endotoxin; therefore, endotoxin did not appear to explain the differences in lung injury. This in vivo model is useful to quantitatively compare the efficacies of parenteral antibiotic administration on Pseudomonas airspace infections.
Collapse
Affiliation(s)
- E J Ernst
- College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Rosen H, Hajdu R, Silver L, Kropp H, Dorso K, Kohler J, Sundelof JG, Huber J, Hammond GG, Jackson JJ, Gill CJ, Thompson R, Pelak BA, Epstein-Toney JH, Lankas G, Wilkening RR, Wildonger KJ, Blizzard TA, DiNinno FP, Ratcliffe RW, Heck JV, Kozarich JW, Hammond ML. Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenem antibiotic. Science 1999; 283:703-6. [PMID: 9924033 DOI: 10.1126/science.283.5402.703] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
A carbapenem antibiotic, L-786,392, was designed so that the side chain that provides high-affinity binding to the penicillin-binding proteins responsible for bacterial resistance was also the structural basis for ameliorating immunopathology. Expulsion of the side chain upon opening of the beta-lactam ring retained antibacterial activity while safely expelling the immunodominant epitope. L-786,392 was well tolerated in animal safety studies and had significant in vitro and in vivo activities against methicillin- and vancomycin-resistant Staphylococci and vancomycin-resistant Enterococci.
Collapse
Affiliation(s)
- H Rosen
- Merck Research Laboratories, Rahway, NJ 07065, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Gill CJ, Jackson JJ, Gerckens LS, Pelak BA, Thompson RK, Sundelof JG, Kropp H, Rosen H. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob Agents Chemother 1998; 42:1996-2001. [PMID: 9687396 PMCID: PMC105722 DOI: 10.1128/aac.42.8.1996] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/1997] [Accepted: 06/03/1998] [Indexed: 11/20/2022] Open
Abstract
MK-826 (formerly L-749,345), is a potent 1-beta-methyl carbapenem with a long half-life and broad spectrum of activity. This compound is presently in phase-II clinical trials. Its activity against a number of gram-positive and gram-negative organisms was compared to those of imipenem (IPM) and eight other beta-lactam agents in two in vivo murine infection models. The distribution in tissue and pharmacokinetic properties of MK-826 and ceftriaxone (CTRX) were also evaluated in CD-1 mice following a single intraperitoneal dose (10 mg/kg of body weight). In addition, concentrations in plasma as well as biliary and urinary recovery of MK-826 were compared to that of CTRX in a cannulated rat model. In a localized murine thigh infection model, MK-826 and IPM were superior to a variety of beta-lactam antibiotics in reduction of Staphylococcus aureus CFU compared with results from nontreated controls (eliminating >/=4 log10 CFU). Similar activities of IPM and MK-826 were observed in a gram-positive bacterial murine systemic infection model. While IPM demonstrated greater efficacy than MK-826 against Enterobacter cloacae (50% effective doses [ED50s] of 0.062 and 0.227 mg/kg, respectively) and Pseudomonas aeruginosa (ED50s of 0.142 and 3.0 mg/kg, respectively) systemic infections, MK-826 was 8- to 350-fold more efficacious than IPM against all other gram-negative organisms in this infection model. In mice, MK-826 demonstrated a higher peak concentration in serum (62.8 versus 42.6 microg/ml) and a larger area under the curve (AUC) (150.8 versus 90.0 microg . hr/ml) than CTRX. The concentrations of MK-826 and CTRX in serum declined slowly, with levels of 3.6 and 2.0 microg/ml remaining, respectively, at 6 h posttreatment. The rat pharmacokinetic model showed the average AUC of MK-826 to be greater than that of CTRX (284 versus 142 microg . hr/ml) following a single 10-mg/kg dose. Also, a half-life of MK-826 longer than that of CTRX (3.2 versus 2.3 h) was observed in this species. The total amount of drug excreted in the bile in 8 h was greater for CTRX (55 to 64% of the dose) than for MK-826 (6 to 12.5% of the dose). Urinary recovery was similar for both antibiotics, with 16 to 18% of the dose recovered over an 8-h period. This excellent broad-spectrum in vivo efficacy of MK-826, together with advantageous pharmacokinetics, supports the argument for its further clinical development.
Collapse
Affiliation(s)
- C J Gill
- Antibiotic Discovery and Development, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Nishimatsu T, Jackson JJ. Interaction of insecticides, entomopathogenic nematodes, and larvae of the western corn rootworm (Coleoptera: Chrysomelidae). J Econ Entomol 1998; 91:410-418. [PMID: 9589627 DOI: 10.1093/jee/91.2.410] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Chemical insecticides and entomopathogenic nematodes have been independently used to suppress corn rootworm damage in maize. We report on the mortality response of larvae of the western corn rootworm, Diabrotica virgifera virgifera LeConte, to the combined treatment with 1 of 3 insecticides (terbufos, fonofos, and tefluthrin) and the entomopathogenic nematode Steinernema carpocapsae Weiser (Mexican strain). Corn rootworm mortality with combinations of the insecticides terbufos or fonofos and S. carpocapsae was typically additive for the 2 agents. Evidence of antagonism between these agents was sometimes observed. The combination of tefluthrin with S. carpocapsae frequently resulted in a synergistic response and a 24% average increase in expected mortality. The influence of the tefluthrin appears to be isolated to an effect on the rootworm larvae. Synergism also was observed when tefluthrin was combined with the nematode Heterorhabditis bacteriophora Poinar (Lewiston strain). The combined use of tefluthrin with an entomopathogenic nematode may offer an integrated approach to increase the efficacy of entomopathogenic nematodes for insect control.
Collapse
Affiliation(s)
- T Nishimatsu
- Northern Grain Insects Research Laboratory, USDA-ARS, Brookings, SD 57006, USA
| | | |
Collapse
|
21
|
Giordano R, Jackson JJ, Robertson HM. The role of Wolbachia bacteria in reproductive incompatibilities and hybrid zones of Diabrotica beetles and Gryllus crickets. Proc Natl Acad Sci U S A 1997; 94:11439-44. [PMID: 9326628 PMCID: PMC23493 DOI: 10.1073/pnas.94.21.11439] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
A rickettsial bacterium in the genus Wolbachia is the cause of a unidirectional reproductive incompatibility observed between two major beetle pests of maize, the western corn rootworm, Diabrotica virgifera virgifera, and the Mexican corn rootworm, D. v. zeae. These subspecies are allopatric except for two known regions of sympatry in Texas and Mexico. We demonstrate that populations of D. v. virgifera, with the exception of two populations in southern Arizona, are infected with a strain of Wolbachia. Populations of D. v. zeae are not infected. Treatment of D. v. virgifera with tetracycline eliminated the Wolbachia and removed the reproductive incompatibility. Similar patterns of reproductive incompatibility exist among taxa of the cricket genus Gryllus. Gryllus assimilis, G. integer, G. ovisopis, G. pennsylvanicus, and G. rubens are infected with Wolbachia whereas G. firmus is usually not. Populations of G. rubens and G. ovisopis carry the same Wolbachia strain, which is distinct from that of G. integer. G. pennsylvanicus is infected with two Wolbachia strains, that found in G. rubens and one unique to G. pennsylvanicus. Moreover, a proportion of G. pennsylvanicus individuals harbors both strains. Wolbachia may have influenced speciation in some members of the genus Gryllus by affecting the degree of hybridization between species. Given that Wolbachia infections are relatively common in insects, it is likely that other insect hybrid zones may be influenced by infections with Wolbachia.
Collapse
Affiliation(s)
- R Giordano
- Department of Entomology, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA.
| | | | | |
Collapse
|
22
|
Abstract
Cognitive function of rats treated with saline (control), THA (8 mg/kg, i.p.), scopolamine (5 mg/kg, i.p.), or a combination of THA (8 mg/kg) and scopolamine (5 mg/kg) was tested in the Morris water maze. The latency to find the platform in the water maze was used to evaluate performance. THA did not significantly alter the latency period as compared to control rats. Scopolamine resulted in a highly significant (p<0.01) increase in latency period (183% increase) as compared to saline treated controls. However, when THA was concurrently administered with scopolamine, it was able to completely reverse the performance decrement induced by scopolamine. Immediately following spatial reference memory testing, animals were sacrificed by decapitation one hour post injection. Brains were immediately removed and the cortex, hippocampus, hypothalamus, and pituitary were dissected and their choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) activity were determined spectrophotometrically. THA administration resulted in a significant increase in ChAT activity in the cortex (23% increase). However, when THA was concurrently administered with scopolamine, a significant increase in ChAT activity was observed in cortex (77% increase), hippocampus (32% increase), hypothalamus (97% increase), and pituitary (92.5% increase). THA administration resulted in a significant decrease in AChE activity (p<0.001) in cortex (62% decrease), hippocampus (78% decrease), and hypothalamus (90% decrease). When tacrine was administered with scopolamine, a significant increase was found in the cortex (197% increase) and the hippocampus (207% increase). In conclusion, the increase in ChAT activity produced by tacrine may in part explain its ability to reverse the scopolamine induced decrease in spatial reference memory and may play a role in its beneficial effect in improving cognitive ability.
Collapse
Affiliation(s)
- J J Jackson
- Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, 32307, USA
| | | |
Collapse
|
23
|
Jackson JJ, Brooks MA. Parasitism of Western Corn Rootworm Larvae and Pupae by Steinernema carpocapsae. J Nematol 1995; 27:15-20. [PMID: 19277256 PMCID: PMC2619578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
Virulence and development of the insect-parasitic nematode, Steinernema carpocapsae (Weiser) (Mexican strain), were evaluated for the immature stages of the western corn rootworm, Diabrotica virgifera virgifera LeConte. Third instar rootworm larvae were five times more susceptible to nematode infection than second instar larvae and 75 times more susceptible than first instar larvae and pupae, based on laboratory bioassays. Rootworm eggs were not susceptible. Nematode development was observed in all susceptible rootworm stages, but a complete life cycle was observed only in second and third instar larvae and pupae. Nematode size was affected by rootworm stage; the smallest infective-stage nematodes were recovered from second instar rootworm larvae. Results of this study suggest that S. carpocapsae should be applied when second and third instar rootworm larvae are predominant in the field.
Collapse
|
24
|
Feied CF, Jackson JJ, Bren TS, Bond OB, Fernando CE, Young VC, Hashemiyoon RB. Allergic reactions to polidocanol for vein sclerosis. Two case reports. J Dermatol Surg Oncol 1994; 20:466-8. [PMID: 8034842 DOI: 10.1111/j.1524-4725.1994.tb03218.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Polidocanol is a sclerosing solution that is highly valued by clinicians and patients for its painlessness, high efficacy, excellent safety profile, low incidence of side effects, and for the rarity of its allergic reactions. Previous estimates of the incidence of allergic reactions have ranged from 0 to 0.06%. OBJECTIVE Improved recognition of systemic allergy to polidocanol is desirable for both clinicians and for patients. We have attempted to describe two cases recently observed in our population and to provide an improved upper-bounds estimate for the true population incidence of allergy to polidocanol. RESULTS We report two recent cases of mild systemic allergic reaction to polidocanol in a population of 689 exposed patients, for an observed incidence of 0.3% in our patient population. We have calculated a 95% confidence upper-bound estimate of 0.91% for the incidence of polidocanol allergy in the general population. CONCLUSION Allergy to polidocanol may be more common than previously recognized. Careful questioning of previously treated patients and more prolonged observation of patients after treatment may yield a larger number of recognized cases.
Collapse
Affiliation(s)
- C F Feied
- Department of Emergency Medicine, George Washington University Medical Center, Washington, DC 20037
| | | | | | | | | | | | | |
Collapse
|
25
|
Jackson JJ, Kropp H, Hurley JC. Influence of antibiotic class and concentration on the percentage of release of lipopolysaccharide from Escherichia coli. J Infect Dis 1994; 169:471-3. [PMID: 8106788 DOI: 10.1093/infdis/169.2.471] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
26
|
Jackson JJ, Kropp H. beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992; 165:1033-41. [PMID: 1583320 DOI: 10.1093/infdis/165.6.1033] [Citation(s) in RCA: 117] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The relative effects of two beta-lactam antibiotics, penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime, upon in vitro induction of lipopolysaccharide (LPS) release were investigated against smooth- and rough-LPS mutant isolates of Pseudomonas aeruginosa. Free LPS liberated from both isolates are 10- to 40-fold higher for ceftazidime-exposed cultures than control or imipenem-treated cultures after 4-8 h at 35 degrees C despite equivalent MICs. Lethalities of filtrates in mice correlated with in vitro endotoxin assay results. Sub-MIC levels of ceftazidime induced filamentation and LPS release without significant bacterial lysis. Amounts released not only matched the quantities achieved at inhibitory concentrations (e.g., 1-, 2-, and 50-times MIC) of ceftazidime but significantly exceeded levels of LPS liberated by exposure to imipenem, less than or equal to 100 times its MIC. Sub-MIC levels of imipenem released relatively small amounts of free LPS while reducing colony counts approximately 2 logs more than equivalent amounts of ceftazidime after 2 h. Data suggest that ceftazidime-induced filamentation releases larger quantities of bioreactive LPS than nonfilamentous fast-lysing imipenem.
Collapse
Affiliation(s)
- J J Jackson
- Merck Institute for Therapeutic Research, Rahway, New Jersey 07065
| | | |
Collapse
|
27
|
Patrick SL, Jackson JJ. Further examination of the equity sensitivity construct. Percept Mot Skills 1991; 73:1091-106. [PMID: 1805166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
This study was conducted to investigate whether a measure of equity sensitivity can predict individual reactions to inequity. The equity sensitivity construct suggests that there are three categories of individual preferences for equity: (1) benevolent individuals prefer their input:outcome ratios be less than those of their comparison others, (2) equity sensitive individuals prefer their input:outcome ratios be equal to those of comparison others, and (3) entitled individuals prefer their input:outcome ratios be higher than those of comparison others. To identify their appropriate equity sensitivity category, 639 undergraduate students and 119 fast-food restaurant employees were administered the Equity Sensitivity Instrument. These subjects were then asked to react to two underreward/overreward scenarios. Analysis indicates that equity sensitivity groups generally exhibit reactions in the direction predicted by the study; however, some inconsistencies require further study. Research should examine why some reactions to inequity are chosen over others and how the longitudinal effects of a work relationship may influence one's reactions to inequity.
Collapse
Affiliation(s)
- S L Patrick
- Department of Management, School of Business Administration, George Mason University, Fairfax, VA 22030
| | | |
Collapse
|
28
|
Abstract
6-(5-Cholesten-3 beta-yloxy)hexyl 1-thio-beta-D-mannopyranoside (L-644,257) enhances natural host resistance in cyclophosphamide-treated mice against Pseudomonas aeruginosa in a dose-dependent manner. It is active sc, im, and ip but not orally. L-644,257 is substantially more protective against P. aeruginosa than its alpha anomer. The beta-L-fucose glycolipid is more effective when given im and ip than sc. The lactose and beta-D-glucose glycolipids were only marginally effective to nonprotective. The 17 beta-steroidal side chain of L-644,257 can be modified without substantial loss of protective activity.
Collapse
Affiliation(s)
- M M Ponpipom
- Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065
| | | | | | | | | | | |
Collapse
|
29
|
Hagmann WK, Ponpipom MM, Jackson JJ, Wood DD, Boltz RC, Zweerink HJ. Steroidal glycolipid, L-644,257, is a potent enhancer of nonspecific host resistance. Int J Immunopharmacol 1990; 12:241-6. [PMID: 2329016 DOI: 10.1016/0192-0561(90)90059-v] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A steroidal glycolipid that enhances the nonspecific cellular response to opportunistic infection in an immunocompromised host has been discovered. A dose dependent response with 6-(5-cholesten-3 beta-yloxy)hexyl 1-thio-beta-D-mannopyranoside, L-644,257, was observed against several infective agents including bacterial, fungal, and viral pathogens in cyclophosphamide-treated mice. A mechanism for this protective action is proposed.
Collapse
Affiliation(s)
- W K Hagmann
- Department of Medicinal Chemical Research, Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey 07065
| | | | | | | | | | | |
Collapse
|
30
|
Zweerink HJ, Gammon MC, Hutchison CF, Jackson JJ, Lombardo D, Miner KM, Puckett JM, Sewell TJ, Sigal NH. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa. Infect Immun 1988; 56:1873-9. [PMID: 3135264 PMCID: PMC259495 DOI: 10.1128/iai.56.8.1873-1879.1988] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Lymphocytes from healthy volunteers and from cystic fibrosis patients were transformed with Epstein-Barr virus and cultured at a limiting dilution to generate lymphoblastoid cell lines that secreted human monoclonal antibodies specific for lipopolysaccharide (LPS) from Pseudomonas aeruginosa. Three cell lines (RM5, FDD7, and 11F9) produced immunoglobulin M (IgM) antibody species that reacted specifically with P. aeruginosa Fisher immunotypes 2, 4, and 5, respectively, and with LPS extracted from these immunotypes. A fourth cell line (9H10) produced a single IgM antibody species that recognized P. aeruginosa immunotypes 3, 6, and 7 and LPS extracted from them. Monoclonal antibodies secreted by cell lines RM5, FDD7, and 11F9 protected neutropenic mice prophylactically against challenge with P. aeruginosa immunotypes 2, 4, and 5, and those secreted by 9H10 protected against P. aeruginosa immunotypes 3 and 6 but did not protect against immunotype 7. In vivo experiments indicated that antibodies protected mice against infection by increasing the rate of bacterial clearance.
Collapse
Affiliation(s)
- H J Zweerink
- Department of Immunology Research, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065-0900
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Zweerink HJ, Gammon MC, Hutchison CF, Jackson JJ, Pier GB, Puckett JM, Sewell TJ, Sigal NH. X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa. Infect Immun 1988; 56:1209-14. [PMID: 3128480 PMCID: PMC259785 DOI: 10.1128/iai.56.5.1209-1214.1988] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
(DBA/N[female] X CBA/2[male])F1 males have been reported to be deficient in producing antibodies against a number of antigens, including carbohydrates (I. Scher, Adv. Immunol. 35:1-71, 1982). We show that F1 male mice, in contrast to females, made less lipopolysaccharide (LPS)-specific antibodies after immunization with heat-inactivated Pseudomonas aeruginosa and had significantly less naturally occurring LPS-specific antibodies. Furthermore, neutropenic males were 50 to 1,000 times more sensitive to challenge with representative isolates belonging to the seven Fisher immunotypes. Administration to neutropenic F1 males of a human monoclonal antibody specific for the O carbohydrates of P. aeruginosa immunotype 2 LPS or administration of serum from rabbits immunized with heat-inactivated P. aeruginosa immunotype 1 raised the level of resistance to bacterial challenge close to that of females. The results show that the X-linked immunodeficient mouse is an excellent model with which to test the protective efficacy of P. aeruginosa-specific monoclonal antibodies.
Collapse
Affiliation(s)
- H J Zweerink
- Department of Immunology Research, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065
| | | | | | | | | | | | | | | |
Collapse
|
32
|
|
33
|
Jackson JJ. Death rates of aged blacks and whites, United States, 1964-1978. Black Scholar 1982; 13:36-48. [PMID: 11614268 DOI: 10.1080/00064246.1982.11414231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
34
|
Jackson JJ, Ryan EA. System for continuous monitoring of point defect concentrations during irradiations and anneals. Rev Sci Instrum 1979; 50:1193. [PMID: 18699359 DOI: 10.1063/1.1135685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
An integrated system, cryostat, electronics, and computer used for detailed resistivity measurements during low-temperature irradiations and anneals of metals is described. The thermal response time and rate of heat removal from the specimens are optimized. The system has excellent stability for extended isothermal anneals; measurements of deviations from Mathiessen's rule are discussed to illustrate this feature. Examples are given of the use of the system to determine dense sets of thermal activation energies during anneals through state I. These determinations are made by linear heating at different rates during recombinations of close Frenkel pairs, and by abruptly and repeatedly changing the annealing temperature during the recovery of more widely separated pairs.
Collapse
Affiliation(s)
- J J Jackson
- Argonne National Laboratory, Argonne, Illinois 60439
| | | |
Collapse
|
35
|
Ramsey EJ, Carey KV, Peterson WL, Jackson JJ, Murphy FK, Read NW, Taylor KB, Trier JS, Fordtran JS. Epidemic gastritis with hypochlorhydria. Gastroenterology 1979; 76:1449-57. [PMID: 437444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Seventeen of 37 healthy volunteers participating in studies of acid secretion and 1 patient with Zollinger-Ellison syndrome became rapidly and profoundly hypochlorhydric. A mild illness with epigastric pain occurred in 9 subjects, usually several days before detection of hypochlorhydria. Gastric mucosal biopsy specimens taken from subjects during hypochlorhydria revealed severe fundal and antral gastritis; however, even when acid secretion was severely depressed, parietal cells were abundant and appeared normal histologically. During hypochlorhydria, gastric permeability to hydrogen, sodium, and lithium was normal in 4 subjects. Serum gastrin concentrations were usually normal, whereas serum pepsinogen concentrations were invariably elevated. Serum parietal cell antibodies were not present. Acid secretion returned to near baseline levels in 14 of 17 subjects after a mean of 126 days (range 53--235); severity of gastritis diminished concurrently in 7 of 10 subjects on whom biopsies were serially performed. An infectious etiology is suspected, although serologic studies and bacterial and conventional viral cultures of stool and gastric juice have not identified a candidate agent.
Collapse
|
36
|
Eylar EH, Jackson JJ, Kniskern PJ. Suppression and reversal of allergic encephalomyelitis in rhesus monkeys with basic protein and peptides. Neurochem Res 1979; 4:249-58. [PMID: 88679 DOI: 10.1007/bf00964148] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
We have extended earlier studies on the suppression of clinically evident experimental allergic encephalomyelitis (EAE) in monkeys, repeated injections of human basis protein. The results confirm that after suppressive treatment, recovered animals remain clinically normal and do not show spontaneous recurrence of symptoms. However, recovered animals are susceptible to EAE upon renewed challenge, and they develop the disease more rapidly and more severely than after the initial challenge; resuppression is also accomplished in these cases by the same methods used previously. The results indicate further that the basic protein or peptide T administered without mycobacteria is effective in suppressing the development of basic protein-induced EAE regardless of the species from which it was derived.
Collapse
|
37
|
Jackson JJ. Special health problems of aged blacks. Aging (Albany NY) 1978:15-20. [PMID: 10239638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
38
|
Karkhanis YD, Zeltner JY, Jackson JJ, Carlo DJ. A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. Anal Biochem 1978; 85:595-601. [PMID: 646115 DOI: 10.1016/0003-2697(78)90260-9] [Citation(s) in RCA: 532] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
39
|
Walls B, Jackson JJ. Factors affecting the use of physicians by menopausal black women. Urban Health 1977; 6:53-5. [PMID: 10235790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
40
|
Hagopian A, Limjuco GA, Jackson JJ, Carlo DJ, Eylar EH. Experimental allergic aspermatogenic orchitis. IV. Chemical properties of sperm glycoproteins isolated from guinea pig testes. Biochim Biophys Acta 1976; 434:354-64. [PMID: 952893 DOI: 10.1016/0005-2795(76)90227-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Of four glycoproteins isolated from guinea pig testes, two were aspermatogenic (types I and IV) and two (types II and III) were inactive. The glycoproteins were rich in carbohydrate, varying from 41.5% to 49.5% carbohydrate by weight. Each glycoprotein had a unique amino acid composition, but in general low levels of tyrosine, tryptophan, and basic amino acids were found along with relatively high contents of serine, threonine, glutamic acid, and proline. Types I and IV glycoproteins were remarkably stable; their aspermatogenic activity was not affected by urea, trypsin, or heating at 100 degrees C in water or in 1 M HCl for 15 min. Carbohydrate analysis revealed little difference in the monosaccharide compositions of types I and IV glycoproteins, except that only the type I contained sialic acid. In contrast, types II and III glycoproteins lacked sialicacid and fucose and contained much less mannose. Both N-acetylglucosamine and N-acetylgalactosamine were present in all four glycoproteins, and they dominated in the types II and III. Fucose and at least 20-25% of the galactose appeared to occupy terminal positions in type IV glycoprotein as shown by their release after 15 min hydrolysis in 1 M HCl. All of the glycoproteins contained a relatively high percentage of galactose by weight, from 12.6 to 19.3%. The molecular weights of the glycoproteins were estimated by sodium dodecyl sulfate gel electrophoresis to be 47000, 105000 and 18000 respectively for the types I, II, and IV; type III glycoprotein showed two major bands, with molecular weights of 41500 and 22800. All the above molecular weight values are probably overestimated because of high carbohydrate content. The molecular weight of type IV glycoprotein was found to be 13000 by ultracentrifugation; a corrected value of 29000 was calculated for type I glycoprotein.
Collapse
|
41
|
Jackson JJ, Hagopian A, Carlo DJ, Limjuco GA, Eylar EH. Experimental allergic aspermatogenic orchitis. II. Some chemical properties of the AP1 protein of the sperm acrosome. Biochim Biophys Acta 1976; 427:251-61. [PMID: 1260000 DOI: 10.1016/0005-2795(76)90301-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The AP1 protein, a unique aspermatogenic protein localized in the sperm acrosome, exists as a single polypeptide chain of 136 amino acids, as shown by a single band on gel electrophoresis in sodium dodecyl sulfate and the recovery of the expected 21 to 22 tryptic peptides on peptide mapping. The AP1 protein appears to exist in a compact, highly stable conformation, as shown by its resistance to trypsin hydrolysis. Its aspermatogenic acitivity is not affected by trypsin treatment, by heating at 99 degrees C for 1 h, by 8 M urea, or by acid conditions. After reduction and alkylation, however, the molecule appears to open up, since it becomes hydrolyzable by trypsin and migrates more slowly on gel electrophoresis at pH 2.7 and 8.6. After alkylation, the AP1 protein still migrates as a single band at pH 2.7. The AP1 protein shows microheterogeneity near its isolectric point at pH 8.6; each of five bands shows the same amino acid analysis. Aggregation was not observed following treatment with dimethylsuberimidate. The molecular weight of 15 000, obtained from gel electrophoresis consists of 136 amino acids with a relatively high content of proline, half cystine, glycine, histidine and tryptophan. No galactose, mannose, fucose, glucose, or hexosamines were found; the AP1 protein is thus not a glycoprotein.
Collapse
|
42
|
Carlo DJ, Hagopian A, Jackson JJ, Limjuco GA, Eylar EH. Experimental allergic orchitis and aspermatogenesis. VI. Transfer of allergic orchitis with immune cells. J Immunol 1976; 116:619-22. [PMID: 1254946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Typical experimental allergic orchitis (EAO) and aspermatogenesis were successfully transferred to strain 13 guinea pigs with peritoneal exudate and lymph node cells from male and female donor guinea pigs (lacking detectable antibody) previously sensitized with 9 mug of highly purified GP1 glucoprotein isolated from the sperm acrosome. Attempts to transfer the disease with circulating antibody from hyperimmunized animals were not successful. These studies support a cell-mediated basis for the immunopathologic events in EAO.
Collapse
|
43
|
Hagopian A, Jackson JJ, Carlo DJ, Limjuco GA, Eylar EH. Experimental allergic aspermatogenic orchitis. III. Isolation of spermatozoal glycoproteins and their role in allergic aspermatogenic orchitis. J Immunol 1975; 115:1731-43. [PMID: 810515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Four glycoproteins (GP1,2,3 and 4) rich in carbohydrate were isolated from guinea pig testes. GP1, 2, and 4 (one or more) were localized in the sperm acrosome by the indirect immunofluorescence technique. Purification consisted of delipidation with chloroform-methanol (2:1), acid extraction at pH 3.0, precipitation with 85% saturated ammonium sulfate, extraction with 5% trichloroacetic acid, and either gel filtration on agarose or ultrafiltration. The final purification steps were isoelectrofocusing or gel filtration on Sephadex G-75 followed by preparative slab gel electrophoresis at pH 8.6. Each glycoprotein appeared homogeneous by gel electrophoresis at pH 2.7 and 8.6, and by immunoelectrophoresis. The crude glycoprotein fraction from the agarose column was resolved into the three major components, GP1, 2, and 3, distinguished by their isoelectric points (pI 3.9, 4.4, and 5.0, respectively), electrophoretic mobilities at pH 8.6, and reactivities with antiserum in immunoelectrophoresis. GP4, isolated by ultrafiltration and Sephadex G-75 chromatography, was differentiated by the same criteria. Approximately 5 mg each of purified GP1, 3, and 4 and 2 to 3 mg of GP2 were isolated from 1000 g of wet guinea pig testes. GP1, 2, and 4 induced precipitating antibody in rabbits and goats. GP1 and GP4 induced allergic aspermatogenic orchitis in guinea pigs, an autoimmune disease characterized by infiltration of mononuclear cells around and within the seminiferous tubules, followed by extensive destruction of the germinal epithelium. The course of the disease induced by 2 mug of either GP1 or GP4 was essentially identical in time course and pathology to that induced by whole testicular homogenates or 1 mug of purified acrosomal protein (AP1).
Collapse
|
44
|
Jackson JJ, Hagopian A, Carlo DJ, Limjuco GA, Eylar EH. Experimental allergic aspermatogenic orchitis. 1. Isolation of a spermatozoal protein (AP1) which induces allergic aspermatogenic orchitis. J Biol Chem 1975; 250:6141-50. [PMID: 238998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
A unique highly soluble aspermatogenic protein (AP1) was isolated from guinea pig testes and was shown by immunofluorescence to occupy the outer surface of the sperm acrosome. This protein is a potent inducer of allergic orchitis and aspermatogenesis; as little as 0.2 mug induced orchitis in 60 percent of guinea pig tested. The AP1 protein, relatively small and neutral, is stable under acid conditions, but at pH 8.6 shows a variety of forms due either to aggregation or polymorphism. The purified AP1 protein appeared homogeneous by polyacrylamide gel electrophoresis at pH 2.7 and in sodium dodecyl sulfate and by immunoelectrophoresis using rabbit antisera to either the purified protein or the testes extract. It also showed a single band on immunodiffusion over a wide concentration range. The purification procedure consisted of delipidation with chloroform/methanol (2/1); acid extraction at pH 3.0; precipitation with 85 percent saturated ammonium sulfate; trichloroacetic acid extraction and gel filtration on Bio-Gel A-1.5; gel filtration on Bio-Gel P-10; chromatography on CM52 cellulose; and preparative gel electrophoresis at pH 2.7. Approximately 20 mg of purified AP1 protein were obtained from 5000 g of wet guinea pig testes. The AP1 protein induced an autoimmune disease characterized by infiltration of mononuclear cells around and within the seminiferous tubules (orchitis), followed by extensive damage and destruction of the germinal cells (aspermatogenesis). The course of the disease induced by this protein (0.5 to 1 mug) was essentially identical with that seen with whole testicular tissue or other purified fractions.
Collapse
|
45
|
Jackson JJ, Hagopian A, Carlo DJ, Limjuco GA, Eylar EH. Experimental allergic aspermatogenic orchitis. 1. Isolation of a spermatozoal protein (AP1) which induces allergic aspermatogenic orchitis. J Biol Chem 1975. [DOI: 10.1016/s0021-9258(19)41170-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
46
|
Eylar EH, Jackson JJ, Bennett CD, Kniskern PJ, Brostoff SW. The chicken A-1 protein. Phylogenetic variation in the amino acid sequence of the encephalitogenic site. J Biol Chem 1974; 249:3710-6. [PMID: 4134751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
47
|
|
48
|
Jackson JJ. Face to face, mind to mind, it sho' nuff ain't no zombie jamboree. J Natl Med Assoc 1972; 64:145-50. [PMID: 5020446 PMCID: PMC2608760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
49
|
|
50
|
|